Carna Biosciences Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	544.45	636	1,625	1,386	2,017	1,133
Revenue Growth (YoY)	-61.14%	-60.86%	17.24%	-31.28%	78.02%	-64.67%
Cost of Revenue	172.12	171	175	171	135	192
Gross Profit	372.33	465	1,450	1,215	1,882	941
Selling, General & Admin	2,422	655	664	603	572	524
Research & Development	-	1,886	1,903	1,882	1,841	1,474
Operating Expenses	2,422	2,541	2,567	2,485	2,413	1,998
Operating Income	-2,050	-2,076	-1,117	-1,270	-531	-1,057
Interest Expense	-35.36	-3	-4	-6	-4	-7
Interest & Investment Income	6.73	14	-	-	-	-
Currency Exchange Gain (Loss)	9.26	26	-	-	14	-9
Other Non Operating Income (Expenses)	-22.32	-42	-5	-3	-3	-5
EBT Excluding Unusual Items	-2,092	-2,081	-1,126	-1,279	-524	-1,078
Asset Writedown	-96.36	-93	-4	-44	-9	-26
Other Unusual Items	-	-	-	-	-	1
Pretax Income	-2,188	-2,174	-1,130	-1,323	-533	-1,103
Income Tax Expense	2	4	22	26	1	8
Net Income	-2,190	-2,178	-1,152	-1,349	-534	-1,111
Net Income to Common	-2,190	-2,178	-1,152	-1,349	-534	-1,111
Shares Outstanding (Basic)	19	18	17	14	13	12
Shares Outstanding (Diluted)	19	18	17	14	13	12
Shares Change (YoY)	5.70%	6.61%	23.37%	7.26%	3.22%	10.64%
EPS (Basic)	-114.82	-121.61	-68.57	-99.06	-42.06	-90.33
EPS (Diluted)	-114.82	-121.61	-68.57	-99.06	-42.06	-90.33
Free Cash Flow	-	-1,387	-1,688	-834	-1,577	-1,324
Free Cash Flow Per Share	-	-77.44	-100.48	-61.24	-124.22	-107.65
Gross Margin	68.39%	73.11%	89.23%	87.66%	93.31%	83.05%
Operating Margin	-376.52%	-326.41%	-68.74%	-91.63%	-26.33%	-93.29%
Profit Margin	-402.24%	-342.45%	-70.89%	-97.33%	-26.47%	-98.06%
Free Cash Flow Margin	-	-218.08%	-103.88%	-60.17%	-78.19%	-116.86%
EBITDA	-	-2,045	-1,082	-1,237	-512	-1,045
EBITDA Margin	-	-	-66.59%	-89.25%	-25.38%	-92.23%
D&A For EBITDA	28	31	35	33	19	12
EBIT	-2,050	-2,076	-1,117	-1,270	-531	-1,057
EBIT Margin	-	-	-68.74%	-91.63%	-26.33%	-93.29%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.